Treatment of Abiotrophia Endocarditis
Treat Abiotrophia defectiva endocarditis with ampicillin or penicillin G (24 million units/24h IV) plus gentamicin (3 mg/kg/24h IV) for 4-6 weeks, using the same regimen as enterococcal endocarditis, with mandatory infectious disease consultation. 1
Primary Treatment Regimen
The American Heart Association 2015 guidelines explicitly address Abiotrophia defectiva (formerly nutritionally variant streptococci) and recommend treating it differently from typical viridans group streptococci due to its higher resistance profile and worse outcomes 1:
- Ampicillin or Penicillin G: 24 million units/24h IV (continuously or in 4-6 divided doses)
- Plus Gentamicin: 3 mg/kg/24h IV as single daily dose for 2 weeks minimum
- Duration: 4 weeks for native valve endocarditis, 6 weeks for prosthetic valve endocarditis
- Infectious disease consultation is mandatory (Class IIa recommendation) 1
Alternative Regimens
For Penicillin-Intolerant Patients
If the patient cannot tolerate β-lactams, vancomycin 30 mg/kg/24h IV in 2 divided doses for 4-6 weeks is reasonable 1. Importantly, when vancomycin is used, gentamicin should NOT be added (Class III recommendation) 1.
Ceftriaxone-Based Option
Ceftriaxone 2g/24h IV plus gentamicin may be considered if the isolate is susceptible to ceftriaxone (Class IIb recommendation) 1. This combination has been used successfully in case reports 2, 3.
Critical Clinical Context
Abiotrophia endocarditis carries significantly higher morbidity and mortality than typical streptococcal endocarditis 4, 5, 6:
- Higher rates of treatment failure and relapse compared to other viridans streptococci
- Frequent embolic complications: stroke, splenic infarcts, mycotic aneurysms occur in up to 40% of cases 2, 7, 6
- Large vegetations: typically >10mm in most reported cases 5
- Valve destruction requiring surgery: occurs in 50-60% of cases 4, 5
Surgical Considerations
Early surgical intervention should be strongly considered in the following scenarios 5:
- Severe heart failure from valve destruction
- Large vegetations (>10mm) with embolic events
- Hemodynamic instability
- Persistent bacteremia despite appropriate antibiotics
The literature shows successful outcomes with early valve replacement, with zero mortality in surgical series compared to higher mortality with medical management alone 5. Surgery should not be delayed if hemodynamic compromise develops.
Key Pitfalls to Avoid
Do not treat as typical viridans streptococci: Abiotrophia requires combination therapy like enterococcal endocarditis, not monotherapy 1
Do not use short-course gentamicin: While typical viridans strep may only need 2 weeks of gentamicin, Abiotrophia often requires longer aminoglycoside exposure given higher failure rates
Do not delay blood cultures: These organisms are fastidious and may require extended incubation or special media supplementation 3, 6. Alert the laboratory that nutritionally variant streptococci are suspected.
Do not underestimate embolic risk: Maintain high suspicion for CNS, splenic, or other embolic events throughout treatment 2, 7, 6
Do not avoid surgery in deteriorating patients: Historical data showed high failure rates with antibiotics alone; modern series demonstrate excellent outcomes with combined medical-surgical approach 5
Monitoring During Treatment
- Serial echocardiography to assess vegetation size and valve function
- Renal function monitoring given aminoglycoside use
- Clinical assessment for embolic phenomena (neurologic exam, abdominal pain)
- Repeat blood cultures to document clearance
- Consider imaging for occult emboli if clinical deterioration occurs
The combination of aggressive antibiotic therapy with low threshold for surgical intervention has dramatically improved outcomes in recent series, with zero mortality and relapse rates in appropriately managed cases 5, 8.